Reduced-pressure, linear wound closing bolsters and systems

Information

  • Patent Grant
  • 11426165
  • Patent Number
    11,426,165
  • Date Filed
    Wednesday, February 20, 2019
    5 years ago
  • Date Issued
    Tuesday, August 30, 2022
    2 years ago
Abstract
A reduced-pressure, linear-wound closing bolster has a pivotable frame that moves from an extended position to a compressed position under the influence of reduced pressure. The closing bolster may have a first closing member, a second closing member, and an interior space. A manifold member is disposed within the interior space and may be coupled to the pivotable frame. When a reduced pressure is applied, the pivotable frame is urged from the extended position to the compressed position. A first gripping member for transmitting a closing force from the first closing member to a first edge of a linear wound may be attached. Likewise, a second gripping member for transmitting a closing force from the second closing member to a second edge of the linear wound may be attached. Systems and methods are also presented.
Description
BACKGROUND

The present invention relates generally to medical treatment systems, and more particularly, to reduced-pressure, linear wound closing bolsters and systems.


Physicians perform millions of surgical procedures each year around the world. Many of the procedures are performed as open surgery and an increasing number are performed using minimally invasive surgery, such as arthroscopic, laparoscopic, and endoscopic procedures. However performed, surgical procedures involve acute wounds, e.g., an incision, in the skin and related tissue. In many instances, the incision is closed at the conclusion of the procedure using a mechanical apparatus, such as staples or sutures, and the wound is merely covered with a dry, sterile bandage.


The use of staples or sutures to close an acute wound may have undesirable side effects. For example, staples and sutures can proximate the wound edges tightly where they are applied, but in between such mechanical closing devices are gaps or areas that are not as tightly closed. This may lead to areas of high stress proximate the closing device interspersed with areas of relatively low stress in between. This may, in turn, influence scarring, healing time, and strength of the wound.


BRIEF SUMMARY

Shortcomings with certain aspects of linear wound care are addressed by the present invention as shown and described in a variety of illustrative embodiments herein. “Linear wound” refers generally to a laceration or incision whether in a line or not. According to an illustrative embodiment, a reduced-pressure, linear-wound closing bolster for managing a linear wound includes a pivotable frame having a first closing member, a second closing member, and an interior space. The pivotable frame is operable to move between an extended position and a contracted position. The closing bolster further includes a manifold member disposed within the interior space, a first gripping member coupled to the first closing member, and a second gripping member coupled to the second closing member. The first gripping member is for transmitting a closing force from the first closing member to a first edge of the linear wound. The second gripping member is for transmitting a closing force from the second closing member to a second edge of the linear wound.


According to another illustrative embodiment, a reduced-pressure, linear-wound closing bolster includes a first closing member for placing on a first side of the linear wound, a second closing member for placing on a second side of the linear wound, and a first connecting member. The bolster also includes a first pivot connector coupling a portion of the first closing member and the connecting member, a second pivot connector coupling a portion of the second member and the connecting member, and a manifold member coupled to an interior surface of the first closing member and an interior surface of the second closing member. The manifold member contracts when placed under a reduced pressure. The bolster also includes an interface fluidly coupled to the manifold for delivering a reduced pressure thereto.


According to another illustrative embodiment, a reduced-pressure, linear wound treatment system includes a closing bolster for placing on the patient's skin over a linear wound and operable to move between an extended position and a compressed position. The closing bolster comprises a pivotable frame having an interior space and a manifold disposed within the interior space and coupled to the pivotable frame. The system includes a sealing subsystem for providing a fluid seal between the closing bolster and the patient, and a reduced-pressure subsystem for delivering a reduced pressure to the sealing subsystem. The sealing subsystem and reduced-pressure subsystem are operable to deliver a reduced pressure to the closing bolster, and the closing bolster is operable under reduced pressure to go to the compressed position and thereby develop an inward force.


According to one illustrative embodiment, a reduced-pressure, anisotropic closing bolster includes an anisotropic manifold member operable under reduced pressure to contract more in a lateral direction than in a longitudinal direction. The anisotropic manifold member includes a plurality of longitudinal manifold members of a flexible manifold material, a plurality of reinforcing members, and an anisotropic bolster body formed by coupling the plurality of longitudinal manifold members and the plurality of reinforcing members. The anisotropic bolster body is operable under reduced pressure to contract more perpendicularly to the plurality of reinforcing members than parallel to the plurality of reinforcing members.


According to another illustrative embodiment, a method of applying a closing force to a linear wound on a patient includes providing a reduced-pressure, linear-wound closing bolster. Wherein the reduced-pressure, linear-wound closing bolster includes a manifold member and a pivotable frame that has an interior space and a first closing member and a second closing member. The first closing member has a first longitudinal edge and a second longitudinal edge. The second closing member has first longitudinal edge and a second longitudinal edge. The method includes placing the second longitudinal edge of the first closing member proximate a first edge of the linear wound and placing the second longitudinal edge of the second closing member proximate a second edge of the linear wound. The method also includes forming a fluid seal between the pivotable frame and the patient's skin, coupling a reduced-pressure subsystem to an interface to the manifold member, and activating the reduced-pressure source.


According to another illustrative embodiment, a method of manufacturing a reduced-pressure, linear-wound closing bolster includes forming a pivotable frame having first closing member, a second closing member, and an interior space, the pivotable frame operable to move between an extended position and a contracted position. The method includes disposing a manifold member within the interior space and providing a first gripping member operable to transmit a closing force from the first closing member to a first edge of a linear wound. The method also includes providing a second gripping member operable to transmit a closing force from the second closing member to a second edge of the linear wound. The method may further include coupling the manifold member to the pivotable frame such that when a reduced pressure is applied, the pivotable frame is urged from the extended position to the contracted position.


According to one illustrative embodiment, a reduced-pressure, linear-wound closing bolster for managing a linear wound includes a first closing member, a second closing member, a pivot connector coupling the first closing member and second closing member, and an interior space formed at least in part by the first closing member and the second closing member. The pivot connector is operable to move between an extended position and a compressed position. The closing bolster further includes a manifold member disposed within the interior space and coupled to the first closing member and second closing member such that when reduced pressure is applied, the pivotable frame is urged from the extended position to the compressed position. The closing bolster also includes a first gripping member for transmitting a closing force from the first closing member to a first edge of a linear wound and a second gripping member for transmitting a closing force from the second closing member to a second edge of the linear wound.


The illustrative embodiments may provide a number of advantages. A couple of examples follow. Technical advantages of the illustrative embodiments are perceived to include that the wound might be able to withstand more force during the healing process. Additionally, the wound edges that otherwise would not be tightly and smoothly approximated are healed in a tight position with the edges approximated. The time for the wound to gain strength may be decreased. It may also reduce the scar formation at the wound. These are just some possible examples.


Other objects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.





BRIEF DESCRIPTION OF THE DRAWINGS

A more complete understanding of the method and apparatus of the present invention may be obtained by reference to the following Detailed Description when taken in conjunction with the accompanying Drawings wherein:



FIG. 1 is a schematic, cross-sectional view of an illustrative embodiment of a reduced-pressure, linear wound closing system;



FIG. 2 is a schematic detail of a first closure member of the illustrative embodiment of FIG. 1;



FIG. 3A is a schematic, cross-sectional view of an illustrative embodiment of a reduced-pressure, linear wound closing bolster shown in an extended position;



FIG. 3B is a schematic, perspective view of the closing bolster of FIG. 3A also shown in the extended position;



FIG. 3C is a schematic, cross-sectional view of the closing bolster of FIGS. 3A and 3B shown in a compression position;



FIG. 4 is a schematic diagram showing one possible pattern for a dynamic reduced pressure delivered to a reduced-pressure, linear wound closure system;



FIG. 5 is a schematic, cross-sectional view of a linear wound showing the development of collagen parallel to the closing force applied; and



FIG. 6 is a schematic, perspective view of another illustrative embodiment of a closing bolster.





DETAILED DESCRIPTION

In the following detailed description of the illustrative embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific preferred embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the invention, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined only by the appended claims.


Referring to FIGS. 1 and 2 an illustrative embodiment of a reduced-pressure linear wound closing system 100 for treating a linear wound 102, such as a laceration or, more typically, an incision 104 is presented. Linear wound 102 has a first edge 106 and a second edge 108. While linear wound 102 may extend to different depths, it is shown as an incision 104 extending through epidermis 110, dermis 112, and into subcutaneous tissue, or hypodermis, 114.


A dressing assembly 118 may be placed over the linear wound 102 and used with reduced pressure to supply an inward, or closing, force 120, and a compressive force 122 may be developed as well. Dressing assembly 118 includes a closing bolster 126 that is moveable between an extended position (e.g., FIG. 1) and a compression position. A sealing subsystem 178 provides a fluid seal between the dressing assembly 118 and the patient's epidermis 110. A reduced-pressure subsystem 188 provides reduced pressure to an interior portion of the dressing assembly 118 and causes the closing bolster 126 to be urged from the extended position to the compressed position and thereby provides the inward, closing force 124 to both edges 106, 108 of the linear wound 102.


Closing force 120 remains primarily within epidermis 110 and dermis 112. The closing force 120 may provide a smooth, tight approximation of edges 106 and 108 of the linear wound 102. In addition, system 100 is operable to deliver a reduced pressure to incision 104 that may also be realized at the level of any subcutaneous voids to help approximate—bring together—the tissues in that region as well as to help remove any air or any other fluids. The term “fluid” as used herein generally refers to gas or liquid, but may also include any other flowable material. A downward (for the orientation of FIG. 1) compression force 122 may also be developed.


The dressing assembly 118 may include closing bolster 126 and over-drape 180. The closing bolster 126 may be formed in many ways and has the effect of developing a closing force 120 when placed under reduced pressure. System 100 may further provide a compressive force 122, and at the same time, manifold reduced pressure to the linear wound 102 for reduced-pressure treatment.


In the illustrative embodiment of FIG. 1, closing bolster 126 is formed with a pivotable frame 130. To form the pivotable frame 130 of FIG. 1, a first closing member 132, second closing member 146, and a connection member 160 are coupled as will be described. The members of pivotable frame 130 may be made of any material, e.g., a medical grade silicone. The members of the pivotable frame 130 may be extruded, pour molded, injection molded, blow molded, or formed by other manufacturing techniques. The pivotable frame 130 is open on the ends (first end and second end, or proximal end and distal end) as the pivotable frame is deployed on the epidermis 110 and over the linear wound 102, but is covered by the over-drape 180 for use.


The first closing member 132 has a first longitudinal edge 134, second longitudinal edge 136, a first lateral edge (analogous to lateral edge 238 in FIG. 3B), second lateral edge (analogous to lateral edge 240 in FIG. 3B), an interior surface 142, and a lateral axis 144 (FIG. 2). Similarly, the second closing member 146 has a first longitudinal edge 148, second longitudinal edge 150, a first lateral edge (analogous to lateral edge 252 in FIG. 3B), second lateral edge (analogous to lateral edge 254 in FIG. 3B), an interior surface 156, and a lateral axis analogous to axis 144 (FIG. 2). The connection member 160 has a first longitudinal edge 162, a second longitudinal edge 164, a first lateral edge (analogous to first lateral edge 266 in FIG. 3B), and a second lateral edge (analogous to second lateral edge 268 in FIG. 3B).


The first longitudinal edge 134 of the first closing member 132 is pivotably coupled by a first pivot connector 170 to the first longitudinal edge 162 of the connection member 160. The first longitudinal edge 148 of the second closing member 146 is pivotably coupled by a second pivot connector 172 to the second longitudinal edge 164 of the connection member 160. Together, the pivotably coupled first closing member 132, second closing member 146, and connection member 160 form the pivotable frame 130 and further defines an interior space 174. In one variation, the pivotable frame 130 may be formed by using a first pivot connector to couple the first longitudinal edge 134 of the first closing member 132 to the first longitudinal edge 148 of the second closing member 146.


The first pivot connector 170 may be any device or system that holds the first longitudinal edge 134 of the first closing member 132 to the first longitudinal edge 162 of the connection member 160 (or first longitudinal edge 143 of the second closing member 146) and allows relative movement. The first pivot connector 170 may be, for example, a piano hinge, a living hinge, butterfly hinge, strap hinge, a filament-tape connection, tape, etc. The pivot connector 170 may also be a relief in a sheet of material that allows the sheet to fold and bend along an edge. The other connectors herein, e.g., connector 172, may also be any type of connector, such as those referenced in this paragraph.


A first gripping member 145 may be associated with the second longitudinal edge 136 of the first closing member 132, and a second gripping member 159 may be associated with the second longitudinal edge 150 of the second closing member 146. The gripping member 145, 159 may be a first adhesive strip 147 and a second adhesive strip 161, respectively. Alternatively, the edges 136, 150 may have high-friction members, e.g., soft silicone, added that are able to provide a friction interface with the skin such that as the edges 136, 150 are moved the skin moves with the edges 136, 150 without any significant slipping therebetween. The gripping member 145 and 159 are operable to transmit the inward, closing forces 120 from the closing members 132 and 146 to the patient's skin and thereby urge the edges 106 and 108 of the linear wound 102 into close approximation.


A manifold member 175 is disposed within the interior space 174 of the pivotable frame 130 and may be coupled to the interior surface 142 of first closing member 132 and to the interior surface 156 of second closing member 146. In an alternative embodiment, the manifold member 175 may not be coupled to the interior space 174 and reduced pressure may primarily move the first closing member 132 and second closing member 146 towards each other. The manifold member 175 contracts when placed under reduced pressure and is operable to distribute a reduced pressure to the linear wound 102. The manifold member 175 may be made from many possible manifold materials.


The term “manifold” as used herein as a noun generally refers to a substance or structure that is provided to assist in applying reduced pressure to, delivering fluids to, or removing fluids from a tissue site. In one illustrative embodiment, the manifold member 175 is made from a porous and permeable foam-like material and, more particularly, a reticulated, open-cell polyurethane or polyether foam that allows good permeability of wound fluids while under a reduced pressure. One such foam material that has been used is the VAC® Granufoam® Dressing available from Kinetic Concepts Inc. (KCI) of San Antonio, Tex. Any material or combination of materials might be used for the bolster material provided that the bolster material is operable to manifold the reduced pressure and contract under reduced pressure. A manifold typically includes a plurality of flow channels or pathways that are interconnected to improve distribution of fluids provided to and removed from the area of tissue around the manifold. Examples of manifolds may include without limitation devices that have structural elements arranged to form flow channels, cellular foam such as open-cell foam, porous tissue collections, and liquids, gels and foams that include or cure to include flow channels. The bolster material might also be a combination or layering of materials; for example, a first bolster layer of hydrophilic foam might be disposed adjacent to a second bolster layer of hydrophobic foam to form the bolster material.


The reticulated pores of the Granufoam® material, that are in the range of about 400 to 600 microns, are helpful in carrying out the manifold function, but other materials may be used. A material with a higher density (smaller pore size) than Granufoam® material may be desirable in some situations. The manifold member 175 may be a reticulated foam that is later felted to a thickness of about ⅓ the manifold member's 175 original thickness. Among the many possible materials, the following might be used: Granufoam® material or a Foamex technical foam (www.foamex.com). In some instances it may be desirable to add ionic silver to the foam in a microbonding process or to add other substances to the manifold member 175 such as antimicrobial agents. The manifold member 175 may be isotropic or anisotropic depending on the exact orientation of the forces 120, 122 that are desired during reduced pressure. The manifold member 175 could also be a bio-absorbable material.


Sealing subsystem 178 may include an over-drape 180, or drape, which has a first side 181 and a second side 182. The over-drape 180 covers the dressing 118 and extends past a peripheral edge 176 of bolster 126 to form a drape extension 183. Drape extension 183 has a first side 184 and a second side 185. A sealing apparatus 186 may be used to seal the drape extension 183 to the patient. Sealing apparatus 186 may take numerous forms, such as an adhesive sealing tape 187, or drape tape or strip; double-side drape tape; adhesive; paste; hydrocolloid; hydrogel; or other sealing device. If a tape 187 is used, the tape 187 may be formed of the same material as the over-drape 180 with a pre-applied, pressure-sensitive adhesive on the second side 185 of the extension 183. An adhesive might also be used to provide a substantially fluid seal between the over-drape 180 and the epidermis 110 of the patient. Before the over-drape 180 is applied to the patient, the adhesive may have removable strips covering the adhesive removed, or the drape 180 may be applied and the tape 187 placed to form a seal.


Over-drape 180 may be an elastomeric material that has pore sizes less than about 20 microns. “Elastomeric” means having the properties of an elastomer and generally refers to a polymeric material that has rubber-like properties. More specifically, most elastomers have elongation rates greater than 100% and a significant amount of resilience. The resilience of a material refers to the material's ability to recover from an elastic deformation. Examples of elastomers may include, but are not limited to, natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, and silicones. Over-drape materials may include a silicone, 3M Tegaderm® drape material, acrylic drape material such as one available from Avery, or an incise drape material.


The over-drape 180 may or may not be coupled to the bolster 126. If coupled, the coupling may occur in many ways. Over-drape 180 and bolster 126 may be coupled using adhesives such as an acrylic adhesive, silicone adhesive, hydrogel, hydrocolloid, etc. Over-drape 180 and bolster 126 may be bonded by heat bonding, ultrasonic bonding, and radio frequency bonding, etc. The coupling may occur in patterns or more completely. Structure might be added to the bond to make the over-drape 180 behave anisotropically in a desired direction, i.e. to make an anisotropic drape material. An anisotropic drape material helps the dressing assembly 118 to primarily move in a given direction, i.e. only about a certain axis or axes. This may be particularly useful in a closing application.


Reduced-pressure subsystem 188 includes a reduced-pressure source 189, which can take many different forms. Reduced-pressure source 189 provides a reduced pressure as a part of system 100. The term “reduced pressure” as used herein generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure of tissue at the tissue site. It is often desirable for the reduced-pressure source 189 to develop a continuous reduced pressure below atmospheric pressure and also to be able to deliver a dynamic pressure, i.e., to vary the reduced pressure in a cycle or operate in a continuous or intermittent mode. The operable range of reduced pressure may vary widely as needed, but would typically include 200 mm Hg below atmospheric. In order to maximize patient mobility and ease, reduced-pressure source 189 may be a battery-powered, single-use reduced-pressure generator. Such a pressure source 189 facilitates application in the operating room and provides mobility and convenience for the patient during the rehabilitation phase.


In the illustrative embodiment of FIG. 1, the reduced-pressure source 189 is shown having a battery compartment 195 and a canister region 190 with windows 191 providing a visual indication of the level of fluid within canister 190. An interposed membrane filter, such as hydrophobic or oleophobic filter, might be interspersed between a conduit, or tubing, 192 and the reduced-pressure source 189.


The reduced pressure developed by reduced-pressure source 189 is delivered through the delivery tube or conduit 192 to an interface 193, which might be an elbow port 194. In one illustrative embodiment, port 194 is a TRAC® technology port available from KCI of San Antonio, Tex. Interface 193 allows the reduced pressure to be delivered to the sealing subsystem 178 and received by the manifold member 175.


In the embodiment of FIGS. 1 and 2, application of reduced pressure from the reduced-pressure subsystem 188 causes the manifold member 175 to contract inward, but because overdrape 180 surrounds the pivotal frame 130, there is also a downward (for the orientation shown) force placed on the pivotal frame 130. In this particular embodiment, it is desirable to orient the members of the pivotal frame 130 so that the downward force will be translated into a contribution to the closing force 120. As shown in FIG. 2, this may be accomplished by placing the closing members 132 and 146 with an inward orientation. For example, first closing member 132 is shown in cross-section having a lateral axis 144 that makes an angle α with a reference line or axis 143 that is normal to epidermis 110. Thus, the inward angle α means that as a force is applied downward on connection member 160, the force will urge first member 132 to pivot about first pivot connection 170 and want to collapse inward. This helps to urge the epidermis 110 in the direction of the linear wound 102.


In operation, reduced-pressure, linear wound closing system 100 may be applied to further assist mechanical closure devices such as sutures or staples already applied, or may be the only and primary closing source for linear wound 102. In either case, the system 100 is applied by placing the first closing member 132 on first wound edge 106 and the second closing member 146 on the second wound edge 108. Gripping member 145 on second longitudinal edge 136 is used to engage first edge 106 of the wound 102. In the particular embodiment shown, the first gripping member 145 is an adhesive strip 147. Thus, the healthcare provider would remove visible backing from the adhesive strip 147 and the adhesive strip 147 would be applied proximate first edge 106. In a similar manner, the second gripping member 159 in this embodiment is an adhesive strip 161, and a backing may be removed and the strip 161 applied proximate the second edge 108 of the linear wound 102. Adhesive strips 147 and 161 are applied near edges 106 and 108 in a manner that places the closing members 132 and 146 at an inward angle as described earlier in connection with FIG. 2. It should be noted that in this particular embodiment, the manifold member 175 has already been placed within interior space 174 formed by the pivotal frame 130, but in other applications the manifold member 175 could be inserted just prior to applying the gripping members 145 and 159 to the epidermis 110. If the overdrape 180 has not already been coupled to an exterior surface of the pivotable frame 130, the overdrape 180 is then placed over the frame 130 and caused to extend beyond the peripheral edges 170 to form the drape extensions 183. In this particular embodiment, adhesive tape 187 is then applied to make sure a fluid seal is formed between drape 180 and the patient's epidermis 110. Reduced-pressure interface 193 is applied and is coupled to delivery tube 192, which in turn is coupled to the reduced-pressure source 189.


Reduced-pressure source 189 may then be activated to deliver reduced pressure to the sealing subsystem 178 and in particular to the manifold member 175. Subject to reduced pressure, manifold member 175 contracts and is compressed down along with the pivotal frame 130. The combination of forces urges the second lateral edges 140 and 154 towards each other and towards wound 102, provides some compression force down, and manifolds reduced pressure to the wound 102.


Referring to FIGS. 3A, 3B, and 3C, another embodiment of a reduced-pressure, linear-wound closure system 200 is presented. Many of the parts are analogous to those of system 100 of FIGS. 1 and 2 and the possible relationship presented as such by simply indexing the numbers by 100. Referring particularly to FIG. 3A, two particular differences are noted. First, the sealing subsystem 278 does not involve the use of an overdrape, but provides a pivotable frame 230 to which a first end cap 263 (FIG. 3B) and a second end cap 265 (FIG. 3B) have been added to form a fluid seal. The interface 293 allows reduced pressure to be supplied to the manifold member 275 without compromising the fluid seal. Second, in application, the closing members 232 and 246 may be allowed to have an outward angle relative to reference line normal to the epidermis (analogous to reference line 143 of FIG. 2). This is because in this embodiment there will not generally be a downward compression force placed on the pivotable frame 230. The closing members 232 and 246 are urged together to provide the inward force 220 primarily by contraction of the manifold member 275. The application of reduced pressure to the manifold member 275 causes the closing bolster 226 to move from an extended position shown in FIGS. 3A and 3B to a compression position shown in FIG. 3C.


Referring to FIG. 3B, system 200 includes pivotal frame 130, which is shown positioned with a lengthwise dimension running parallel to wound axis 203 of linear wound 202. Linear wound 202 has first edge 206 and second edge 208. The first closing member 232 has first lateral edge 238 and a first longitudinal edge 234. The second closing member 246 has a first lateral edge 252 and a second lateral edge 254. The second closing member 246 also has first longitudinal edge 248 and second longitudinal edge 250.


End caps 263 and 265 may be formed in a number of different ways to provide a fluid seal to the ends of the pivotal frame 130. In this particular embodiment, they are shown as adhesive portions of an overdrape material that have been applied to cover the end pieces.


In systems 100 and 200, the reduced pressure delivered by reduced pressure subsystems 188 and 288 may be supplied in a continuous mode or a dynamic reduced pressure mode. In a dynamic mode, the pressure is varied in any number of different types of patterns. For example, referring to FIG. 4, one particular pattern for the application of reduced pressure is presented. The ordinate axis 310 gives the reduced pressure. It should be understood that an increase in reduced pressure here means that a lower gauge pressure would be shown. The abscissa axis 312 gives the elapsed time. Thus, in this particular pattern, the reduced pressure is ramped up to a baseline level 314 and then varied, in this instance, in a sinusoidal pattern between a greater reduced pressure level 316 and a lower reduced pressure 318. This variation in reduced pressure causes micromotion of the wound by varying the closing forces, e.g., the variation of the closing forces 120 and 220 of the embodiments of FIG. 1 and FIG. 3.


Referring now to FIG. 5, one of the beneficial effects encouraged by use of the dynamic pressure, such as the illustration given in connection with FIG. 4, is presented. A linear wound 402 through epidermis 410, dermis 412, and even into subcutaneous tissue 414 is shown. Linear wound 402 has been subjected to dynamic micromotion for forces 420 which may have been generated by a system such as system 100 or system 200, FIG. 1 and FIG. 3, respectively. The micromotion causes the collagen 416 to be deposited in the wound 402 with an orientation that is parallel to the forces 420.


Referring now to FIG. 6, another embodiment of a system for providing a closing force to a linear wound is presented. In this system, an anisotropic bolster 526 is formed with an anisotropic body 528. The anisotropic body 528 comprises an anisotropic manifold member operable under reduced pressure to contract more in a lateral direction, i.e., parallel to force 520, than in a longitudinal, or lengthwise, direction, i.e., perpendicular to force 520.


The anisotropic body may be formed in many ways. As one illustrative embodiment, the bolster body 528 may be formed by utilizing a plurality of flexible, or compressible, manifold members 530 and a plurality of reinforcing longitudinal members 532. The plurality of flexible manifold members 530 may be analogous to the material from which manifold members 175 and 275 were made in previously described embodiments. The reinforcing longitudinal members 532 are formed of a material, or reinforcing material, that inhibits compression along one or more axes or directions. The reinforcing material may also inhibit expansion along one or more axes. The reinforcing material may inhibit both compression and expansion along one or more axes or directions. In one illustrative embodiment, the reinforcing longitudinal members 532 are filaments combined with the manifold members 530 to form the bolster body 528. It will be appreciated that for the orientation shown, the resulting anisotropic bolster body 528 will be able to contract or compress in a first direction 534, but not in a substantial way in a second direction 536.


In operation, the anisotropic closing bolster 526 will be placed down on a linear wound with the lengthwise dimension of the plurality of reinforcing members 532 running parallel to the wound, i.e., with the linear wound substantially parallel to direction 536. An overdrape analogous to drape 180 of system 100 may be applied over the bolster 526 and an interface, which is analogous to interface 193 of FIG. 1, may be applied in order to deliver reduced pressure. When reduced pressure is delivered to the anisotropic closing bolster 526, it will contract in the first direction 534 and this causes inward forces 520 to be directed on both edges of the wound, providing a closing force. The reduced pressure supplied to anisotropic bolster 526 may be dynamically varied as previously discussed or provided in a constant mode.


It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not just limited but is susceptible to various changes and modifications without departing from the spirit thereof.

Claims
  • 1. An apparatus for providing reduced pressure to treat a wound, comprising: a bolster body adapted to be positioned on the wound and to apply a closing force in a first direction across opposing sides of the wound, the bolster body comprising: a plurality of manifold members adapted to compress and to distribute reduced pressure to the wound when the bolster body is exposed to reduced pressure, anda plurality of filaments combined with the manifold members and adapted to inhibit compression in a second direction orthogonal to the first direction; andan over-drape adapted to cover the bolster body and the wound to form an internal space for receiving reduced pressure;wherein the bolster body is adapted to contract in the first direction to apply the closing force on the wound when reduced pressure is applied to the internal space.
  • 2. The apparatus of claim 1, wherein the manifold members are formed from a porous material.
  • 3. The apparatus of claim 1, wherein the manifold members comprise an open-cell foam material.
  • 4. The apparatus of claim 3, wherein the open-cell foam material has a pore size in the range of about 400 μm to about 600 μm.
  • 5. The apparatus of claim 1, wherein the manifold members comprise an open-cell, polyurethane foam material.
  • 6. The apparatus of claim 1, wherein the manifold members comprise an open-cell, polyether foam material.
  • 7. The apparatus of claim 1, wherein the manifold members comprise a layer of hydrophilic foam and a layer of hydrophobic foam.
  • 8. The apparatus of claim 1, wherein the manifold members include a plurality of flow channels to facilitate the distribution of reduced pressure.
  • 9. The apparatus of claim 1, wherein the manifold members are formed from an isotropic material.
  • 10. The apparatus of claim 1, wherein the filaments are substantially non-compressive in a third direction orthogonal to the first direction and the second direction and adapted to inhibit compression of the bolster body in the third direction.
  • 11. The apparatus of claim 1, wherein the filaments are substantially compressive in a third direction orthogonal to the first direction and the second direction, and wherein the bolster body is adapted to apply a compressive force to the wound in the third direction when reduced pressure is applied to the internal space.
  • 12. The apparatus of claim 1, wherein the manifold members comprise a single manifold and the filaments are disposed substantially in parallel within the single manifold to form the bolster body.
  • 13. The apparatus of claim 1, wherein the manifold members comprise manifold layers and the filaments are disposed substantially in parallel within the manifold members to form the bolster body.
  • 14. The apparatus of claim 1, wherein the plurality of filaments are substantially non-compressive and adapted to reinforce the manifold members.
  • 15. The apparatus of claim 1, wherein the plurality of filaments are coupled to the manifold members.
  • 16. The apparatus of claim 1, wherein the filaments are adapted to be positioned substantially parallel to the opposing sides of the wound and the second direction.
  • 17. An apparatus for providing reduced pressure and a closing force to treat a wound, comprising: a bolster body adapted to be positioned on the wound and comprising: at least one manifold member adapted to distribute reduced pressure and to compress in at least a first direction orthogonal to opposing sides of the wound, andat least one filament combined with the manifold member and adapted to inhibit compression of bolster body in at least a second direction orthogonal to the first direction; andan over-drape adapted to cover the bolster body and the wound to form an internal space for receiving reduced pressure;wherein the bolster body is adapted to contract in the first direction to apply the closing force and to distribute reduced pressure when reduced pressure is applied to the internal space.
  • 18. The apparatus of claim 17, wherein the at least one filament is substantially non-compressive and adapted to reinforce the at least one manifold member.
  • 19. The apparatus of claim 17, wherein the at least one filament is coupled to the at least one manifold member.
  • 20. The apparatus of claim 17, wherein the at least one filament is adapted to be positioned substantially parallel to the opposing sides of the wound and the second direction.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/050,182, filed Feb. 22, 2016 which is a continuation of U.S. patent application Ser. No. 13/954,703, filed Jul. 30, 2013, now U.S. Pat. No. 9,295,587 which is a divisional application of U.S. patent application Ser. No. 13/456,201, filed Apr. 25, 2012, now U.S. Pat. No. 8,523,832 which is a divisional application of U.S. patent application Ser. No. 12/475,388, filed May 29, 2009 now U.S. Pat. No. 8,187,237 which claims the benefit, under 35 USC § 119(e), of the filing of U.S. Provisional Patent Application Ser. No. 61/078,114, entitled “Reduced-Pressure, Linear-Wound Treatment System,” filed Jul. 3, 2008; and U.S. Provisional Patent Application Ser. No. 61/057,803, entitled “Reduced-Pressure, Linear Wound Closing Bolster and System,” filed May 30, 2008. All of these provisional applications are incorporated herein by reference for all purposes.

US Referenced Citations (295)
Number Name Date Kind
1195430 Angier Aug 1916 A
1355846 Rannells Oct 1920 A
1638043 Lee Aug 1927 A
1845630 Scholl Feb 1932 A
2452345 Anseimo Oct 1948 A
2547758 Keeling Apr 1951 A
2632443 Lesher Mar 1953 A
2682873 Evans et al. Jul 1954 A
2896618 Schaefer Jul 1959 A
2910763 Lauterbach Nov 1959 A
2969057 Simmons Jan 1961 A
3026874 Stevens Mar 1962 A
3066672 Crosby, Jr. et al. Dec 1962 A
3367332 Groves Feb 1968 A
3419006 Warwick Dec 1968 A
3520300 Flower, Jr. Jul 1970 A
3568675 Harvey Mar 1971 A
3648692 Wheeler Mar 1972 A
3682180 McFarlane Aug 1972 A
3826254 Mellor Jul 1974 A
3892229 Taylor et al. Jul 1975 A
3903882 Augurt Sep 1975 A
3969561 Marshall Jul 1976 A
4080970 Miller Mar 1978 A
4091804 Hasty May 1978 A
4096853 Weigand Jun 1978 A
4121582 Masso Remiro Oct 1978 A
4139004 Gonzalez, Jr. Feb 1979 A
4165748 Johnson Aug 1979 A
4184510 Murry et al. Jan 1980 A
4224945 Cohen Sep 1980 A
4233969 Lock et al. Nov 1980 A
4245630 Lloyd et al. Jan 1981 A
4256109 Nichols Mar 1981 A
4261363 Russo Apr 1981 A
4266545 Moss May 1981 A
4275721 Olson Jun 1981 A
4284079 Adair Aug 1981 A
4297995 Golub Nov 1981 A
4333468 Geist Jun 1982 A
4373519 Errede et al. Feb 1983 A
4375217 Arkans Mar 1983 A
4382441 Svedman May 1983 A
4392853 Muto Jul 1983 A
4392858 George et al. Jul 1983 A
4419097 Rowland Dec 1983 A
4430998 Harvey et al. Feb 1984 A
4465485 Kashmer et al. Aug 1984 A
4475909 Eisenberg Oct 1984 A
4480638 Schmid Nov 1984 A
4525166 Leclerc Jun 1985 A
4525374 Vaillancourt Jun 1985 A
4540412 Van Overloop Sep 1985 A
4543100 Brodsky Sep 1985 A
4548202 Duncan Oct 1985 A
4551139 Plaas et al. Nov 1985 A
4569348 Hasslinger Feb 1986 A
4572814 Naylor et al. Feb 1986 A
4605399 Weston et al. Aug 1986 A
4608041 Nielsen Aug 1986 A
4612230 Liland et al. Sep 1986 A
4640688 Hauser Feb 1987 A
4655754 Richmond et al. Apr 1987 A
4663352 Onofrj May 1987 A
4664662 Webster May 1987 A
4710165 McNeil et al. Dec 1987 A
4722332 Saggers Feb 1988 A
4727868 Szycher et al. Mar 1988 A
4733659 Edenbaum et al. Mar 1988 A
4743232 Kruger May 1988 A
4751133 Szycher et al. Jun 1988 A
4758220 Sundblom et al. Jul 1988 A
4770490 Gruenewald et al. Sep 1988 A
4787888 Fox Nov 1988 A
4795435 Steer Jan 1989 A
4826494 Richmond et al. May 1989 A
4838883 Matsuura Jun 1989 A
4840187 Brazier Jun 1989 A
4863449 Therriault et al. Sep 1989 A
4865026 Barrett Sep 1989 A
4872450 Austad Oct 1989 A
4878901 Sachse Nov 1989 A
4897081 Poirier et al. Jan 1990 A
4902565 Brook Feb 1990 A
4906233 Moriuchi et al. Mar 1990 A
4906240 Reed et al. Mar 1990 A
4917112 Kalt Apr 1990 A
4919654 Kalt Apr 1990 A
4941882 Ward et al. Jul 1990 A
4953565 Tachibana et al. Sep 1990 A
4969880 Zamierowski Nov 1990 A
4985019 Michelson Jan 1991 A
5000741 Kalt Mar 1991 A
5018515 Gilman May 1991 A
5037397 Kalt et al. Aug 1991 A
5086170 Luheshi et al. Feb 1992 A
5092858 Benson et al. Mar 1992 A
5100396 Zamierowski Mar 1992 A
5106629 Cartmell et al. Apr 1992 A
5134994 Say Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5160315 Heinecke et al. Nov 1992 A
5167613 Karami et al. Dec 1992 A
5176663 Svedman Jan 1993 A
5215522 Page et al. Jun 1993 A
5232453 Plass et al. Aug 1993 A
5261893 Zamierowski Nov 1993 A
5278100 Doan et al. Jan 1994 A
5279550 Habib et al. Jan 1994 A
5298015 Komatsuzaki et al. Mar 1994 A
5306798 Horn et al. Apr 1994 A
5342376 Ruff Aug 1994 A
5344415 DeBusk et al. Sep 1994 A
5358494 Svedman Oct 1994 A
5376067 Daneshvar Dec 1994 A
5380294 Persson Jan 1995 A
5423737 Cartmell et al. Jun 1995 A
5429593 Matory Jul 1995 A
5435009 Schild et al. Jul 1995 A
5437622 Carion Aug 1995 A
5437651 Todd et al. Aug 1995 A
5489262 Cartmell et al. Feb 1996 A
5497788 Inman et al. Mar 1996 A
5520629 Heinecke et al. May 1996 A
5527293 Zamierowski Jun 1996 A
5538502 Johnstone Jul 1996 A
5549584 Gross Aug 1996 A
5556375 Ewall Sep 1996 A
5607388 Ewall Mar 1997 A
5628230 Flam May 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5653244 Shaw Aug 1997 A
5714225 Hansen et al. Feb 1998 A
5792088 Felder et al. Aug 1998 A
5844013 Kenndoff et al. Dec 1998 A
5866249 Yarusso et al. Feb 1999 A
5944017 Tweedle Aug 1999 A
5950238 Klein Sep 1999 A
5973221 Collyer et al. Oct 1999 A
6071267 Zamierowski Jun 2000 A
6086450 Mankovitz Jul 2000 A
6109267 Shaw et al. Aug 2000 A
6135116 Vogel et al. Oct 2000 A
6162960 Klein Dec 2000 A
6176868 Detour Jan 2001 B1
6213840 Han Apr 2001 B1
6241747 Ruff Jun 2001 B1
6270910 Jaeger et al. Aug 2001 B1
6287316 Agarwal et al. Sep 2001 B1
6345623 Heaton et al. Feb 2002 B1
6361397 Mankovitz et al. Mar 2002 B1
6420622 Johnston et al. Jul 2002 B1
6440093 McEwen et al. Aug 2002 B1
6458109 Henley et al. Oct 2002 B1
6488643 Tumey et al. Dec 2002 B1
6493568 Bell et al. Dec 2002 B1
6500112 Khouri Dec 2002 B1
6528697 Knutson et al. Mar 2003 B1
6553998 Heaton et al. Apr 2003 B2
6566576 Komerska et al. May 2003 B1
6648862 Watson Nov 2003 B2
6685681 Lockwood et al. Feb 2004 B2
6752794 Lockwood et al. Jun 2004 B2
6814079 Heaton et al. Nov 2004 B2
6824533 Risk, Jr. et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6867342 Johnston et al. Mar 2005 B2
D503509 Bell et al. Apr 2005 S
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
7004915 Boynton et al. Feb 2006 B2
7070584 Johnson et al. Jul 2006 B2
7090647 Mimura et al. Aug 2006 B2
7135007 Scott et al. Nov 2006 B2
7144294 Bell et al. Dec 2006 B2
7195624 Lockwood et al. Mar 2007 B2
7201063 Taylor Apr 2007 B2
7201263 Osada et al. Apr 2007 B2
7214202 Vogel et al. May 2007 B1
7316672 Hunt et al. Jan 2008 B1
7338482 Lockwood et al. Mar 2008 B2
7361184 Joshi Apr 2008 B2
7381859 Hunt et al. Jun 2008 B2
7455681 Wilke et al. Nov 2008 B2
7504549 Castellani et al. Mar 2009 B2
7520872 Biggie et al. Apr 2009 B2
7532953 Vogel May 2009 B2
7534927 Lockwood et al. May 2009 B2
7569742 Haggstrom et al. Aug 2009 B2
7699831 Bengtson et al. Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7846141 Weston Dec 2010 B2
8062273 Weston Nov 2011 B2
8100848 Wilkes et al. Jan 2012 B2
8129580 Wilkes et al. Mar 2012 B2
8216198 Heagle et al. Jul 2012 B2
8241261 Randolph et al. Aug 2012 B2
8251979 Malhi Aug 2012 B2
8257327 Blott et al. Sep 2012 B2
8398614 Blott et al. Mar 2013 B2
8399730 Kazala, Jr. et al. Mar 2013 B2
8449509 Weston May 2013 B2
8529548 Blott et al. Sep 2013 B2
8535296 Blott et al. Sep 2013 B2
8551060 Schuessler et al. Oct 2013 B2
8568386 Malhi Oct 2013 B2
8641691 Fink et al. Feb 2014 B2
8679081 Heagle et al. Mar 2014 B2
8722959 Wilkes et al. May 2014 B2
8834451 Blott et al. Sep 2014 B2
8926592 Blott et al. Jan 2015 B2
9017302 Vitaris et al. Apr 2015 B2
9095468 Kazala, Jr. et al. Aug 2015 B2
9198801 Weston Dec 2015 B2
9211365 Weston Dec 2015 B2
9289542 Blott et al. Mar 2016 B2
9572719 Long et al. Feb 2017 B2
9750641 Kazala, Jr. et al. Sep 2017 B2
10143593 Kazala, Jr. et al. Dec 2018 B2
10265071 Seegert Apr 2019 B2
20010029956 Argenta et al. Oct 2001 A1
20010043943 Coffey Nov 2001 A1
20020007014 Hyde et al. Jan 2002 A1
20020077661 Saadat Jun 2002 A1
20020115951 Norstrem et al. Aug 2002 A1
20020120185 Johnson Aug 2002 A1
20020143286 Tumey Oct 2002 A1
20030040691 Griesbach et al. Feb 2003 A1
20030109816 Lachenbruch et al. Jun 2003 A1
20030139697 Gilman Jul 2003 A1
20030212359 Butler Nov 2003 A1
20040006319 Lina et al. Jan 2004 A1
20040030304 Hunt et al. Feb 2004 A1
20040039415 Zamierowski Feb 2004 A1
20040064111 Lockwood et al. Apr 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040127836 Sigurjonsson et al. Jul 2004 A1
20040242119 Francis Dec 2004 A1
20040243073 Lockwood et al. Dec 2004 A1
20050059918 Sigurjonsson et al. Mar 2005 A1
20050070858 Lockwood et al. Mar 2005 A1
20050101940 Radl et al. May 2005 A1
20050142331 Anderson et al. Jun 2005 A1
20050209574 Boehringer Sep 2005 A1
20050222544 Weston Oct 2005 A1
20050228329 Boehringer et al. Oct 2005 A1
20060041247 Petrosenko et al. Feb 2006 A1
20060064049 Marcussen Mar 2006 A1
20060079852 Bubb et al. Apr 2006 A1
20060149171 Vogel et al. Jul 2006 A1
20060173253 Ganapathy et al. Aug 2006 A1
20060189910 Johnson et al. Aug 2006 A1
20060213527 Argenta et al. Sep 2006 A1
20060264796 Flick et al. Nov 2006 A1
20070021697 Ginther et al. Jan 2007 A1
20070027414 Hoffman et al. Feb 2007 A1
20070032755 Walsh Feb 2007 A1
20070044801 Mathis et al. Mar 2007 A1
20070066946 Haggstrom et al. Mar 2007 A1
20070078366 Haggstrom et al. Apr 2007 A1
20070129707 Blott et al. Jun 2007 A1
20070135777 Greene et al. Jun 2007 A1
20070167884 Mangrum et al. Jul 2007 A1
20070185426 Ambrosio et al. Aug 2007 A1
20070185463 Mulligan Aug 2007 A1
20070219497 Johnson et al. Sep 2007 A1
20070219513 Lina et al. Sep 2007 A1
20070219532 Karpowicz et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070255193 Patel et al. Nov 2007 A1
20080004549 Anderson et al. Jan 2008 A1
20080009812 Riesinger Jan 2008 A1
20080026023 Tauer et al. Jan 2008 A1
20080039763 Sigurjonsson et al. Feb 2008 A1
20080071207 de Luis et al. Mar 2008 A1
20080071214 Locke et al. Mar 2008 A1
20080076844 Van Sumeren et al. Mar 2008 A1
20080103462 Wenzel et al. May 2008 A1
20080103489 Dahners May 2008 A1
20080119802 Riesinger May 2008 A1
20090043268 Eddy et al. Feb 2009 A1
20090047855 Seth et al. Feb 2009 A1
20090125004 Shen et al. May 2009 A1
20090177051 Arons et al. Jul 2009 A1
20090204084 Blott et al. Aug 2009 A1
20090204085 Biggie et al. Aug 2009 A1
20090227968 Vess Sep 2009 A1
20090234307 Vitaris Sep 2009 A1
20090264807 Haggstrom et al. Oct 2009 A1
20090293887 Wilkes et al. Dec 2009 A1
20090299257 Long et al. Dec 2009 A1
20120220963 Hunt et al. Aug 2012 A1
20140163491 Schuessler et al. Jun 2014 A1
20150080788 Blott et al. Mar 2015 A1
Foreign Referenced Citations (101)
Number Date Country
550575 Mar 1986 AU
745271 Mar 2002 AU
755496 Dec 2002 AU
2005436 Jun 1990 CA
2468309 Jul 2003 CA
2560068 Oct 2005 CA
2651833 Nov 2007 CA
1545991 Nov 2004 CN
101277734 Oct 2008 CN
26 40 413 Mar 1978 DE
39 07 522 Apr 1990 DE
43 06 478 Sep 1994 DE
29 504 378 Sep 1995 DE
20 2006 007877 Jul 2006 DE
102005007016 Aug 2006 DE
0100148 Feb 1984 EP
0117632 Sep 1984 EP
0161865 Nov 1985 EP
0330373 Aug 1989 EP
0358302 Mar 1990 EP
0421465 Apr 1991 EP
0424165 Apr 1991 EP
0691113 Jan 1996 EP
0756854 Feb 1997 EP
1018967 Jul 2000 EP
2282788 Dec 2016 EP
1163907 Oct 1958 FR
2661821 Nov 1991 FR
692578 Jun 1953 GB
1574066 Sep 1980 GB
2 195 255 Apr 1988 GB
2 197 789 Jun 1988 GB
2 220 357 Jan 1990 GB
2 235 877 Mar 1991 GB
2 329 127 Mar 1999 GB
2 333 965 Aug 1999 GB
H08154964 Jun 1996 JP
H10356 Jan 1998 JP
2000-189427 Jul 2000 JP
2000210386 Aug 2000 JP
2002-078730 Mar 2002 JP
2003-116907 Apr 2003 JP
2004-160220 Jun 2004 JP
2006-141908 Jun 2006 JP
2006219776 Aug 2006 JP
2006239213 Sep 2006 JP
4129536 Aug 2008 JP
71559 Apr 2002 SG
8002182 Oct 1980 WO
8704626 Aug 1987 WO
90010424 Sep 1990 WO
9205755 Apr 1992 WO
1993000056 Jan 1993 WO
93009727 May 1993 WO
199415562 Jul 1994 WO
94020041 Sep 1994 WO
199420152 Sep 1994 WO
199514451 Jun 1995 WO
9605873 Feb 1996 WO
1997005838 Feb 1997 WO
199711658 Apr 1997 WO
9718007 May 1997 WO
9901173 Jan 1999 WO
9913793 Mar 1999 WO
0007653 Feb 2000 WO
2000061206 Oct 2000 WO
200102478 Jan 2001 WO
01034223 May 2001 WO
200189431 Nov 2001 WO
200185248 Nov 2001 WO
200220067 Mar 2002 WO
2002083046 Oct 2002 WO
2003017898 Mar 2003 WO
2003057071 Jul 2003 WO
2003057307 Jul 2003 WO
2003077989 Sep 2003 WO
2003086262 Oct 2003 WO
2003101385 Dec 2003 WO
2004047695 Jun 2004 WO
2004060413 Jul 2004 WO
2005034797 Apr 2005 WO
2005082435 Sep 2005 WO
2005091884 Oct 2005 WO
2005123170 Dec 2005 WO
2006012745 Feb 2006 WO
2007030599 Mar 2007 WO
2007031762 Mar 2007 WO
2007033679 Mar 2007 WO
2007041642 Apr 2007 WO
2007085396 Aug 2007 WO
2007120138 Oct 2007 WO
2008013869 Jan 2008 WO
2008013896 Jan 2008 WO
2008020209 Feb 2008 WO
2008041926 Apr 2008 WO
2008054312 May 2008 WO
2008063281 May 2008 WO
2008104609 Sep 2008 WO
2009019496 Feb 2009 WO
2009047524 Apr 2009 WO
2009071926 Jun 2009 WO
Non-Patent Literature Citations (82)
Entry
Louis C. Argenta, MD and Michael J. Morykwas, PHD; Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience; Annals of Plastic Surgery; vol. 38, No. 6, Jun. 1997; pp. 563-576.
Susan Mendez-Eatmen, RN; “When wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24.
James H. Blackburn II, MD et al.: Negative-Pressure Dressings as a Bolster for Skin Grafts; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457; Lippincott Williams & Wilkins, Inc., Philidelphia, PA, USA.
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK.
S.E. Greer, et al. “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487.
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639.
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80.
International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995.
PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999.
PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999.
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & Apr. 29, 1997.
PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997.
Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5.
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof.
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof.
Yusupov. Yu.N., et al; “Active Wound Drainage”, Vestnki Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof.
Davydov, Yu.A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirugi, Oct. 1988, pp. 48-52, and 8 page English translation thereof.
Davydov, Yu.A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof.
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63.
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24.
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2.
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534.
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81.
Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213.
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221.
Svedman, P. et al: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous of Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133.
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986); pp. 94-96 (copy and certified translation).
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246.
G. {hacek over (Z)}ivadinovi?, V. ?uki?, {hacek over (Z)}. Maksimovi?, ?. Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (copy and certified translation).
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585.
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (copy and certified translation).
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370.
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513.
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I).
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax,” Journal of the American Medical Association 64 (1915), pp. 1548-1549.
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211.
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”).
V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”).
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”).
V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians; Jul. 2007.
European Search Report for corresponding Application No. 16171527.1 dated Dec. 9, 2016.
Japanese Office Action corresponding to Application No. 2016104769, dated Mar. 7, 2017.
Laskin, et al.; “Minimally Invasive Total Knee Replacement Through a Mini-Midvastus Incision: An Outcome Study,” Surgical Technology International XIII, 2004; 231-8.
A. Dee, “The successful management of a dehisced surgical wound with TNP following Femoropopliteal bypass”, Journal of Wound Care, vol. 16, No. 1, Jan. 2007.
Ogazon, Use of Vacuum-Assisted Closure in the Treatment of Surgical Infection Sites Cir. Mar.-Apr. 2006; 74(2): 107-13 (Spanish).
Timmenga, “The Effects of Mechanical Stress on Healing Skin Wounds: An Experimental Study in Rabbits Using Tissues Expansions,” British Journal of Plastic Surgery 1991; 44(7): 514-519.
Cunningham “Development of in-vitro Model to Simulate Dermal Wound Bed Interaction with GranuFoam and Gauze Dressing under Sub Atmospheric Pressure” RPT 111-05-02, Device Implant Innovations 2006.
Delalleau, A., et al, “Characterization of the Mechanical Properties of Skin by Inverse Analysis Combined with the Indentation Test” Journal of Biomechanics, 2006; pp. 1603-1610.
Pailler-Mattei, C., “Caracte; Risation Me' Canique et Tribologizue de la Peau Humain In Vivo”, 2004-31.
Khatyr, F., “Model of the Viscoelastic Behavior of Skin In Vivo and Study of Anisotropy”, Skin Research and Technology 2004; pp. 96-103.
Wilkes, “3D Strain Measurement in Soft Tissue: Demonstration of a Novel Inverse Finite Element Model Algorithm on MicroCT Images of a Tissue Phantom Exposed to Negative Pressure Wound Therapy,” Journal of the Mechanical Behavior of Biomedical Materials (2008), pp. 1-16.
Diridollou, “In vivo Model of the Mechanical Properties of the Human Skin under Suction”, Skin Research and Technology, 2000; 6:214-221.
Woo, “Structural Model to Describe the Non-Linear Stress-Strain Behavior for Parallel-Fibered Collagenous Tissues,” Journal of Biomechanical Engineering, Nov. 1989, vol. 111/361.
International Search Report and Written Opinion dated Oct. 20, 2009; PCT International Application No. PCT/US2009/045747.
International Search Report and Written Opinion dated Oct. 16, 2009; PCT International Application No. PCT/US2009/045752.
International Search Report and Written Opinion dated Oct. 14, 2009; PCT International Application No. PCT/US2009/045746.
International Search Report and Written Opinion dated Oct. 27, 2009; PCT International Application No. PCT/US2009/045744.
International Search Report and Written Opinion dated Oct. 26, 2009; PCT International Application No. PCT/US2009/045751.
International Search Report and Written Opinion dated Nov. 11, 2009; PCT International Application No. PCT/US2009/045754.
International Search Report and Written Opinion dated Oct. 21, 2009; PCT International Application No. PCT/US2009/045749.
International Search Report and Written Opinion dated Feb. 25, 2010; PCT International Application No. PCT/US2009/045750.
International Search Report and Written Opinion dated Mar. 12, 2010; PCT International Application No. PCT/US2009/045755.
Product Information for OptSiteTM dressing. Accessed Aug. 14, 2011.
International Search Report and Written Opinion dated Nov. 12, 2009; PCT International Application No. PCT/US2009/045753.
International Search Report and Written Opinion dated Aug. 30, 2011 for PCT International Application No. PCT/US2011/034300.
Extended European Search Report for corresponding Eurpean Application No. 12171212.9 dated Nov. 14, 2012.
European Search Report for EP 14182278.3 dated Jan. 7, 2015.
International Search Report and Written Opinion dated Aug. 20, 2009; PCT International Application No. PCT/US2009/045743.
European Search Report for EP 09770665.9, dated Feb. 25, 2015.
Canadian Examiner's Report for Corresponding Application No. 2980359, dated Jul. 31, 2018.
A Prospective, Blinded, Randomized, Controlled Clinical Trial of Topical Negative Pressure Use in Skin Grafting, Elias Moisidis, Tim Heath, Catherine Boorer, Kevin Ho, Anand K. Deva, Sydney, Australia, From the Department of Plastic and Maxillofacial Surgery, Liverpool Hospital. Received for publication Mar. 25, 2003; revised Oct. 1, 2003.
The Vacuum Assisted Closure Device, A Method of Secunng Skin Grafts and Improving Grafts Survival; Lynette A. Scherer, MD; Stephen Shiver, MD; Michael Chang, MD; J_ Wayne Meredith, MD; John T. Owings. MD; From the Departments of Surgery, University of California-Davis Medical Center, Sacramento (Ors. Sherer and Owings), and Wake Forest University Baptist Medical Center, Winston-Salem, NC (Ors. Shiver, Chang, and Meredith); Arch SurQNol 137, AuQ 2002; www.archsurQ.com.
Examination Report for corresponding EP 09770659.2, dated Sep. 4, 2013.
Extended European Search Report corresponding to Application No. 171645070, dated Jul. 18, 2017.
European Examination Report for corresponding EP09770663.4, dated Aug. 9, 2013.
Chintamani V.S. et al. : “Half Versus Full Vacuum Suction Drainage After Modified Radical Mastectomy for Breast Dancer—a Prospective Randomized Clinical Trial [ISRCTN24484328]”, BMC Cancer, 2005, vol. 5, article 11; abstract.
Communication pursuant to Rule 114(2) EPC for corresponding EP Application 09770664.2, dated Aug. 22, 2013.
Canadian Office Action dated May 25, 2016, corresponding to Canada Application No. 2,725,945.
Mexican Office Action corresponding to Application No. MX/a/2010/013134, dated Oct. 26, 2017.
Ndian Examination Report for corresponding Application No. 9029/DELNP/2010, dated Nov. 23, 2017.
Extended European Search Report for corresponding Application No. 161998968, dated Mar. 1, 2017.
Japanese Notice of Rejection Corresponding to Application No. 2017-235283, dated Aug. 6, 2019.
Related Publications (1)
Number Date Country
20190175175 A1 Jun 2019 US
Provisional Applications (2)
Number Date Country
61078114 Jul 2008 US
61057803 May 2008 US
Divisions (2)
Number Date Country
Parent 13456201 Apr 2012 US
Child 13954703 US
Parent 12475388 May 2009 US
Child 13456201 US
Continuations (2)
Number Date Country
Parent 15050182 Feb 2016 US
Child 16280817 US
Parent 13954703 Jul 2013 US
Child 15050182 US